Skip to content

Can antioxidants supplementation improve ICSI/IVF outcomes in women undergoing IVF/ICSI treatment cycles? Randomised controlled study.

Antioxidants and IVF/ICSI outcomes.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23255
Enrollment
170
Registered
2011-03-19
Start date
2011-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANTIOXIDANTS

Interventions

At the start of down regulation treatment or previous cycle precceding the IVF cycle, patients will be randomized into two groups. The antioxidant group (study group) will receive oral antioxidants me
IBSA, Egypt) from cycle day 2 or 3 and continued until the day of ovulation induction. A fixed dose of HP-FSH will be used, either 225 IU - 300 IU per day for the first 5 days, according to age, body
2. Different downrgulation protocols will be used either daily midluteal long GnRH protocol, 01 mg, SC, Decapeptyl( Ferring,) or flexible GnRH antagonist ganirelix (Cetrotide 0.25 mg
Organon) is initiated and continued up to and including the day of ovulation induction
3. When at least two follicles reach a size of 18 mm, both groups will receive hCG (10,000 IU SC) for final oocyte maturation, followed by OPU 34-36 hours later.

Sponsors

Egyptian International Fertility IVF center- Private center, Cairo , Egypt
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female age 18 – 45 years; 2. Menstrual cycles between 25 and 34 days; 3. Absence of uterine abnormalities; 4. Absence of uterine abnormalities; 5. Has an indication for IVF/ICSI.

Exclusion criteria

Exclusion criteria: Poor sperm quality with counts less than 1 million or azospermia.

Design outcomes

Secondary

MeasureTime frame
1. Implantation rate; 2. Biochemical and clinical pregnancy rate; 3. Duration of stimulation; 4. Amount of FSH and adverse events.

Primary

MeasureTime frame
1. Number of retrieved oocytes; 2. Number of mature oocytes; 3. Number of embryos obtained.

Contacts

Public ContactMohamed A.F. Youssef

Post Office Box 109

mmfatah@yahoo.com / m.a.youssef@amc.uva.nl+20 2148088826

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)